Clinical trial NCT03484130: Prospective Phenotyping of Autonomous Aldosterone Secretion
Official title: Prospective Phenotyping of Autonomous Aldosterone Secretion: a Cohort Study
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Aldosterone Disorder
Adrenal Gland Disease
Blood Pressure
Keywords: primary aldosteronism
Lead sponsor: Brigham and Women's Hospital
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
First posted: 2018-03-30
Enrollment: 100
Sex: ALL
Minimum age (years): 35
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Normotensive individuals who have a reasonably high risk of developing hypertension in the next few years

Brief summary: This prospective cohort study will investigate the physiology and progression of autonomous aldosterone secretion.

Detailed description: Primary aldosteronism is a disorder wherein aldosterone is secreted by the adrenal gland(s) independent of its physiologic regulators and cannot be appropriately suppressed with sodium/volume loading. Primary aldosteronism is a common cause of hypertension and has a relatively high prevalence. This is important since the excessive mineralocorticoid receptor activation in primary aldosteronism contributes to adverse cardiovascular and renal outcomes and death. For these reasons, it is critical that autonomous aldosteronism be detected early in its course since appropriate treatment interventions may prevent cardiovascular disease.

In addition to severe and overt primary aldosteronism in hypertension, human studies have shown that milder forms of primary aldosteronism can exist even among normotensive individuals. Detailed physiologic studies have shown that normotensive individuals with a phenotype of autonomous aldosterone secretion have greater cardiometabolic risk factors, impaired renal-vascular function, and a higher risk for developing incident hypertension. Further, older age is associated with greater autonomous aldosterone secretion, suggesting that autonomous aldosterone secretion may progress over time. A better understanding of the prevalence and progression of this type of "subclinical" autonomous aldosterone secretion may inform our understanding of the pathogenesis of hypertension and cardiometabolic diseases.

This protocol is designed to be a prospective longitudinal study that will carefully characterize the degree of autonomous aldosterone secretion among high-risk normotensive individuals and follow them longitudinally with repeated phenotyping study visits to assess the progression and severity of autonomous aldosterone secretion over time and its relevance to cardiovascular health. Phenotyping visits will include measurements of the renin-angiotensin-aldosterone system under controlled posture and variable sodium intakes and repeated assessments of blood pressure.

This prospective cohort study will provide insights into normal and abnormal aldosterone physiology over time and how it may contribute to time- or age-dependent hypertension and cardiometabolic risk.

Eligibility criteria: Inclusion Criteria:

1. Age 35-70 years
2. Systolic blood pressure of 120-135 mmHg and/or diastolic blood pressure of 75-85 mmHg
3. At least one, or more, of the following:

   * BMI ≥ 25 kg/m2
   * Family history of hypertension prior to the age of 60 years in a parent or sibling
   * Diabetes with a hemoglobin A1c \< 9%
4. If systolic blood pressure 115-135 mmHg and/or diastolic blood pressure 70-85 mmHg, must have two or more of the following:

   * BMI ≥ 25 kg/m2
   * Family history of hypertension prior to the age of 60 years in a parent or sibling
   * Diabetes with a hemoglobin A1c \< 9%

Exclusion Criteria:

* Known history of hypertension or use of antihypertensive medications
* Known history of stroke, coronary artery disease, myocardial infarction, heart failure, cerebral or aortic aneurysm, or preeclampsia.
* Active cancer that is being treated with chemotherapeutic agents
* Pregnancy
* Breast feeding
* Daily use of prescribed opioid medications
* Illicit drug use (cocaine, heroin, methamphetamine)
* Daily non-steroidal anti-inflammatory medication use
* Daily use of glucocorticoids
* Electrocardiogram that shows evidence of prior myocardial infarction, atrial arrhythmia, left or right bundle branch blocks.
* Estimated glomerular filtration rate \< 60 mL/min/1.73m2
* Active and untreated hyper- or hypo-thyroidism
* Abnormal screening laboratories (comprehensive metabolic panel, complete blood count, thyrotropin)
* BMI ≥ 45 kg/m2

Primary outcomes:
measure: Change in renin
timeFrame: 10 years
Secondary outcomes:
measure: SASSI
timeFrame: 5 years
measure: Blood pressure
timeFrame: 5 years
Other outcomes:
Locations:
city: Boston
country: United States
facility: Brigham and Women's Hospital
state: Massachusetts
Study officials:
affiliation: Brigham and Women's Hospital
name: Anand Vaidya, MD, MMSc
role: PRINCIPAL_INVESTIGATOR
References: